Needham analyst N. Quinn Bolton maintains Marvell Technology (NASDAQ:MRVL) with a Buy and raises the price target from $47 to $50.
Chardan Initiates Coverage On These ‘Intriguing Small-Cap Stories”
Chardan Research initiated coverage on Avidity Biosciences Inc (NASDAQ:RNA) with a Buy rating and a price target of $29 and Dyne Therapeutics Inc (NASDAQ:DYN) with…